Prompted by the promising perspectives derived from combining MelaSil_Ag NPs with a biomodulator for improving cell internalization and targeting, a systematic study was undertaken to explore the potential of human serum albumin (HSA) to modify the NPs to target breast cancer cells. This evidence concerns the gene ALB and breast carcinoma.